As the biology of the CCL17/CCL22-CCR4 chemokine–receptor axis is being further elucidated, interest in its constituent molecules as potential therapeutic targets for the treatment of allergies, autoimmune diseases, and cancer has been growing. This evidence concerns the gene CCR4 and allergic disease.